U.S. administers 211.6 million doses of COVID-19 vaccines - CDC
- Wall Street ends with broad sell-off on spiking inflation fears
- Bitcoin Falls as Musk Says Tesla (TSLA) Will Suspend Vehicle Purchases Using Bitcoin, Citing Use of Fossil Fuels in Mining
- Fed Has Already Changed its Policy Due to Inflation, Market Gambling Fears - Dick Bove
- U.S. consumer prices post largest gain since 2009 as inflation ramps up
- Bill Ackman said has he been working on a transaction for Pershing Square Tontine (PSTH) for months
FILE PHOTO: A health care worker fills a syringe with Moderna COVID-19 vaccine as California opens up vaccine eligibility to any residents 16 years and older during the outbreak of coronavirus disease (COVID-19) in Chula Vista, California, U.S., April 15,
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Reuters) - The United States has administered 211,581,309 doses of COVID-19 vaccines in the country as of Monday morning, the U.S. Centers for Disease Control and Prevention (CDC) said on Monday.
A total of 209,406,814 vaccine doses had been administered by April 18, the CDC said.
The agency said 132,321,628 people had received at least one dose while 85,365,180 people were fully vaccinated as of Monday.
The CDC tally includes two-dose vaccines from Moderna and Pfizer/BioNTech as well as Johnson & Johnson's one-shot vaccine as of 6:00 a.m. ET on Monday.
A total of 7,780,750 vaccine doses have been administered in long-term care facilities, the agency said.
(Reporting by Dania Nadeem in Bengaluru; Editing by Devika Syamnath)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- More than 4,000 Indians die of COVID-19 for second straight day
- Australia's Crown, suitor Star vow to go cashless in casinos, regulator says
- Universal valued at $40 billion, more than parent Vivendi: documents
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!